Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01059786
Recruitment Status : Recruiting
First Posted : February 1, 2010
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Tracking Information
First Submitted Date  ICMJE January 29, 2010
First Posted Date  ICMJE February 1, 2010
Last Update Posted Date June 6, 2019
Actual Study Start Date  ICMJE July 1, 2010
Estimated Primary Completion Date December 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 20, 2018)
Overall response rate (PR+CR) [ Time Frame: Time of progression ]
Proportion of patients receiving pentostatin + rituximab and bendamustine + rituximab who achieve response
Original Primary Outcome Measures  ICMJE
 (submitted: January 29, 2010)
To determine if pentostatin + rituximab and bendamustine + rituximab are each associated with adequate response rates (ORR=PR+CR) in patients with relapsed HCL, and, if so, to select which combination is likely to be superior. [ Time Frame: 5-6 months after beginning the protocol ]
Change History Complete list of historical versions of study NCT01059786 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 30, 2018)
Response rate [ Time Frame: 4 years ]
Compare rituximab plus either pentostatin or bendamustinein terms of MRD-free survival, disease-free survival, overall survival and toxicity, including to CD4+ T-cells.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 29, 2010)
To compare rituximab plus either pentostatin or bendamustine in terms of MRD-free survival and disease-free survival, and toxicity, including to CD4+ T-cells. To determine if MRD levels and tumor markers correlate with response
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Official Title  ICMJE Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Brief Summary

Background:

  • Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies. One nonstandard treatment for HCL is rituximab, an antibody that binds to the cancer cells and helps the immune system destroy them. By combining rituximab with other anti-cancer drugs, researchers hope to determine whether the combined drugs are successful in treating HCL.
  • Pentostatin and bendamustine are two anti-cancer drugs that have been used to treat different kinds of blood and immune system cancers. Bendamustine is approved to treat other kinds of leukemia and lymphoma, but it has not been used to treat HCL. Pentostatin has been used for more than 20 years to treat HCL, but it has not been combined with rituximab in official clinical trials.

Objectives:

  • To determine whether rituximab with either pentostatin or bendamustine is a more effective treatment for HCL than rituximab alone.
  • To determine whether pentostatin or bendamustine is a more effective treatment for HCL when combined with rituximab.

Eligibility:

- Individuals at least 18 years of age who have been diagnosed with hairy cell leukemia that has not responded well to or has relapsed after standard HCL therapies.

Design:

  • The study will last for four treatment cycles of 28 days each.
  • Prior to the study, participants will be screened with a full medical history and physical exam, bone marrow biopsy (if one has not been performed in the last 6 months), computed tomography (CT) or ultrasound scan, tumor measurements, and other tests as required by the researchers. Participants will provide blood and urine samples at this time as well.
  • Rituximab with bendamustine: Participants will receive rituximab on Days 1 and 15 of each cycle and bendamustine on Days 1 and 2 of each cycle, for a total of four cycles.
  • Rituximab with pentostatin: Participants will receive rituximab on Days 1 and 15 of each cycle and pentostatin on rituximab on Days 1 and 15 of each cycle, for a total of four cycles.
  • Participants will have regular tests during the treatment cycles, including bone marrow biopsies and CT or ultrasound scans. Participants will also provide regular blood and urine samples to assess the results of treatment....
Detailed Description

Background:

  • Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and durations. Once resistant, patients after multiple relapses can die of disease-related cytopenias.
  • Rituximab alone in 51 patients from 5 trials who had cytopenias and at least 1 prior purine analog resulted 10 complete + 10 partial remissions (CR+PR= ORR 39%).
  • Rituximab with cladribine gives high CR rates in 1st or 2nd line, but is not standard.
  • While cladribine use is more common for 1st and 2nd line, pentostatin is often used for subsequent treatment because of < 100% cross-resistance.
  • Retrospective published data for pentostatin plus rituximab in HCL include 7 of 7 responses with 6 (86%) CRs, and there are no prospective data.
  • Recombinant immunotoxins targeting CD25 (LMB-2) and CD22 (BL22 and HA22) are highly active in purine analog resistant HCL. Palliative pentostatin-rituximab is often used off-protocol for patients with immunogenicity needing more therapy.
  • Bendamustine is approved for early treatment of CLL, and is effective with rituximab for relapsed/refractory CLL. Its use in HCL is unreported.
  • CRs with minimal residual disease (MRD) by immunohistochemistry of bone marrow biopsy (BMBx IHC), can relapse early. Tests for HCL MRD in blood or marrow include flow cytometry (FACS) or PCR using consensus primers. The most sensitive MRD test in HCL is real-time quantitative PCR using sequence-specific primers (RQ-PCR).
  • Of 5 HCL-specific trials listed on Cancer.gov, 2 are phase II trials of cladribine + rituximab in 1st and 2nd line (1 randomized at NIH, 1 non-randomized at MDA), and 3 NIH phase I-II trials of recombinant immunotoxins BL22, HA22 and LMB-2.

Objectives:

-Primary:

--To determine if pentostatin + rituximab and bendamustine + rituximab are each associated with adequate response rates (ORR=PR+CR) in patients with relapsed HCL, and, if so, to select which combination is likely to be superior.

Eligibility:

  • HCL needing therapy, either > 2 prior courses of purine analog, or 1 course purine analog plus >1 course rituximab if < 1 year response to the 1 course purine analog, diagnosis of HCL variant (HCLv), or unmutated IGHV4-34+expressing HCL/HCLv.
  • Prior treatment, ineligibility for, or patient refusal of recombinant immunotoxin.

Design:

  • Rituximab 375 mg/m(2) on day 1, 15 for 6 x 28-day cycles (all 68 patients).
  • Randomize: 1) 28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each

cycle 2) 28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.

Initial tolerability study: 12 patients receive rituximab + bendamustine (nonrandom), including 6 at 70 mg/ m(2) and 6 at 90 mg/ m(2) of bendamustine.

  • Statistics: If > 14/28 respond, can conclude with 90% power that response > 40% in that arm. >80% probability of selecting the better arm if true response probability is approximately 40-50% on the inferior arm and >15% higher on the superior arm.
  • Stratify to equalize the % of patients/arm refractory to last course of purine analog.
  • Accrual Ceiling: 74, including 0-6 nonrandomized patients/arm with prior noresponse to the other regimen. Allow crossover after failure of either regimen.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hairy Cell Leukemia
Intervention  ICMJE
  • Drug: Pentostatin
    28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
  • Drug: Rituximab
    Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 68 patients)
  • Drug: Bendamustine
    28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
Study Arms  ICMJE
  • Experimental: Arm 1
    Rituximab + Bendamustine at 70 mg/m2 for initialtolerability study (closed)
    Interventions:
    • Drug: Rituximab
    • Drug: Bendamustine
  • Experimental: Arm 2
    Rituximab + bendamustine at 90 mg/m2 for initialtolerability study (closed)
    Interventions:
    • Drug: Pentostatin
    • Drug: Rituximab
  • Experimental: Arm 3
    Rituximab + Bendamustine
    Interventions:
    • Drug: Pentostatin
    • Drug: Rituximab
  • Active Comparator: Arm 4
    Rituximab + Pentostatin
    Interventions:
    • Drug: Pentostatin
    • Drug: Rituximab
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 28, 2015)
74
Original Estimated Enrollment  ICMJE
 (submitted: January 29, 2010)
68
Estimated Study Completion Date  ICMJE December 31, 2020
Estimated Primary Completion Date December 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • INCLUSION CRITERIA:

2.1.1.1. Evidence of HCL by flow cytometry of blood or a solid (lymph node) mass, confirmed by the Laboratory of Pathology, NCI, including positivity for CD19, CD22, CD20, and CD11c. Patients with flow cytometry consistent with HCL variant (HCLv) are eligible, including those with CD25 and/or CD103 negative disease.

2.1.1.2.BMBx or BMA consistent with HCL, confirmed by NIH Laboratory of Pathology, NCI, or the Department of Laboratory Medicine, Clinical Center, NIH, unless the diagnosis can be confirmed from a solid (lymph node) mass..

2.1.1.3. Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment, if applicable.

Neutropenia (ANC less than 1000 cells/microl).

Anemia (Hgb less than 10g/dL).

Thrombocytopenia (Plt less than 100,000/microl).

Absolute lymphocyte count (ALC) of greater than 5,000 cells/microL

Symptomatic splenomegaly.

Enlarging lymph nodes greater than 2cm.

Repeated infections requiring oral or i.v. antibiotics.

Patients who have eligible blood counts within 4 weeks from enrollment will not be considered ineligible if subsequent blood counts prior to enrollment fluctuate and become ineligible up until the time of enrollment.

2.1.1.4. One of the following:

  • At least 2 prior courses of purine analog
  • 1 prior course of purine analog plus greater than or equal to1 course of rituximab if the response to the course of purine analog lasted less than 1 year.
  • Diagnosis of HCL variant (HCLv)
  • Unmutated (>98% homology to germline) IGHV4-34+expressing HCL/HCLv

2.1.1.5. ECOG performance status (100) of 0-3

2.1.1.6. Patients must be able to understand and give informed consent.

2.1.1.7. Creatinine less than or equal to 1.5 or creatinine clearance greater than or equal to 60 ml/ml.

2.1.1.8. Bilirubin less than or equal to 2 unless consistent with Gilbert s (total/direct greater than 5), ALT and AST less than or equal to 3 x upper limits of normal.

2.1.1.9. No other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry, or cladribine for 6 months prior to study entry, unless progressive disease more than 2 months after cladribine is documented.

2.1.1.10. Age at least 18

2.1.1.11. Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment.

EXCLUSION CRITERIA:

2.1.2.1. Presence of active untreated infection

2.1.2.2. Uncontrolled coronary disease or NYHA class III-IV heart disease.

2.1.2.3. Known infection with HIV, hepatitis B or C.

2.1.2.4. Pregnant or lactating women.

2.1.2.5. Presence of active 2nd malignancy requiring treatment. 2nd malignancies with low activity which do not require treatment (i.e. low grade prostate cancer, basal cell or squamous cell skin cancer) do not constitute exclusions.

2.1.2.6. Inability to comply with study and/or follow-up procedures.

2.1.2.7. Presence of CNS disease

2.1.2.8. Patients with history of non-response to both pentostatin plus rituximab and to bendamustine plus rituximab.

2.1.2.9. Receipt of a live vaccine within 4 weeks prior to randomization. Efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied. It is recommended that a patient s vaccination record and possible requirements be reviewed. The patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment. Review of the patient s immunization status for the following vaccinations is recommended: tetanus; diphtheria; influenza; Pneumococcal polysaccharide; Varicella; measles, mumps and rubella (MMR); and hepatitis B. Patients who are considered to be at high risk for hepatitis B virus (HBV) infection and for whom the investigator has determined that immunization is indicated should complete the entire HBV vaccine series at least 4 weeks prior to participation in the study.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 100 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Theresa Yu, R.N. (301) 480-6195 theresa.yu@nih.gov
Contact: Robert J Kreitman, M.D. (301) 480-6187 kreitmar@mail.nih.gov
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01059786
Other Study ID Numbers  ICMJE 100025
10-C-0025
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Robert J Kreitman, M.D. National Cancer Institute (NCI)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date November 30, 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP